On June 27, Aurobindo Pharma reported receiving a warning notice from capital markets regulator Securities and Exchange Board of India for failing to disclose information on an ongoing audit of one of its manufacturing facilities in Hyderabad and findings from the US Food and Drug Administration. The company "disclosed very limited and restricted information", according to the SEBI warning letter, …
